Last year a jury awarded $101.2 million to Medtronic, finding that NuVasive had infringed on three of the company’s spine implant patents. Medtronic sought a permanent injunction of the verdict to prevent further sales of those products, which the district court judge denied in tentative and non-binding rulings on the post-trial motions, according to the report.
After the denial, NuVasive shares rose over 19 percent until the market closed for the day.
Related Articles on Orthopedic Devices:
Interventional Spine Receives FDA Clearance for Spine Device
Zimmer’s 2.9% Sales Increase Driven by Foreign Markets
DJO Net Sales Top $1B in 2011 Preliminary Report
